EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An Immunohistochemistry-based Decision Flowchart to De-escalate Axillary Surgery for Biopsy-Diagnosed Pure Ductal Carcinoma In Situ (DCIS) of the Breast

Julia A M Riggi, Christine Galant, Caroline Bouzin, Aurélie Daumerie, Naïma Benhaddi, Hilde Vernaeve, Nathanael Dubois, Maud Vassilieff, Mirela Roman, Latifa Fellah, Amandine Gerday, Carolien H M van Deurzen und 2 weitere

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2026.101040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Julia A M Riggi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cliniques universitaires Saint-Luc, Brussels, Belgium; Université catholique de Louvain (UCLouvain), Institut de Recherche E…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Biomarkers, Tumor. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Foundation Against Cancer, Fund for Scientific Research, Fondation contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of ductal carcinoma in situ (DCIS) of the breast and invasive breast cancer (IBC) is considerably similar, despite their different biology. Axillary surgery is increasingly de-escalated by omitting sentinel lymph node biopsies (SLNBs) for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) early-stage IBCs, supported by recent clinical trial data. The American Society of Clinical Oncology/National Comprehensive Cancer Network guidelines recommend SLNB for patients with DCIS treated with mastectomy, although some patients treated with lumpectomy still undergo SLNB. We aimed to identify markers to predict the upstaging risk after a biopsy diagnosis of pure DCIS and provide data to justify de-escalation of axillary surgery for patients with DCIS. The following features were retrospectively reviewed for 258 DCIS: nuclear grade, necrosis, histological calcifications, stromal architecture, DCIS architecture, tumor-infiltrating lymphocytes, estrogen receptor (ER), and progesterone receptor. Immunohistochemistry for HER2 was performed. Statistical analyses were performed with upstaging to (micro-)invasive carcinoma as the outcome variable. Clinical and radiological data were included in multivariable logistic regression. Solid architecture (P = .001) and radiological size (>20 mm; P = .025) were independently associated with upstaging risk. Two algorithms were created, based on surgery type, ER/HER2 status, and upstaging risk. High upstaging risk was defined as solid architecture and/or radiological size >20 mm (model 1) or solid architecture and/or absent histological calcifications (model 2). Each model identified a single patient with upstaging to ER+/HER2- IBC, without a positive SLNB. Both models showed that SLNBs may be safely omitted in low-risk ER+/HER2- DCIS, even when treated with mastectomy. However, model 1 identified fewer patients as low risk than model 2: 10 patients (17%) vs 32 patients (55%) within the group of 58 ER+/HER2- DCIS treated with mastectomy. Model 2 seems, therefore, more promising for further validation. Routine implementation of this decision flowchart requires retrospective validation before moving to prospective clinical trials but could substantially de-escalate axillary surgery for future patients with DCIS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingBiomarkers, TumorHumansFemaleImmunohistochemistryMiddle AgedAgedAdultRetrospective StudiesSentinel Lymph Node BiopsyErb-b2 Receptor Tyrosine KinasesAxillaAged, 80 and overClinical Decision-Making

Stichwörter der Autor:innen

ductal carcinoma in situ of the breastestrogen receptorhuman epidermal growth factor receptor 2immunohistochemistrysentinel lymph nodeupstaging risk

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Cliniques universitaires Saint-Luc, Brussels, Belgium; Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC), Morphology Department (MORF), Brussel…
  • Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC) 2IP Platform (Imaging Department) (RRID: SCR_023378), Brussels, Belgium.
  • Department of Pathology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
  • Department of Gynecology, Breast Clinic, Clinique Saint-Jean, Brussels, Belgium.
  • Department of Gynecology, Breast Clinic Isala, Centre Hospitalier et Universitaire (CHU) Saint-Pierre, Brussels, Belgium.
  • Department of Gynecology, Breast Clinic, Institut Roi Albert II (IRAII), Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Förderung

  • Foundation Against Cancer
  • Fund for Scientific Research
  • Fondation contre le Cancer
  • Fondation Saint-Luc

Zitieren

APA

Riggi, J. A. M., Galant, C., Bouzin, C., Daumerie, A., Benhaddi, N., Vernaeve, H., Dubois, N., Vassilieff, M., Roman, M., Fellah, L., Gerday, A., van Deurzen, C. H. M., Berlière, M., & Van Bockstal, M. R. (2026). An Immunohistochemistry-based Decision Flowchart to De-escalate Axillary Surgery for Biopsy-Diagnosed Pure Ductal Carcinoma In Situ (DCIS) of the Breast. Modern Pathology. https://doi.org/10.1016/j.modpat.2026.101040

Vancouver

Riggi JAM, Galant C, Bouzin C, Daumerie A, Benhaddi N, Vernaeve H, et al. An Immunohistochemistry-based Decision Flowchart to De-escalate Axillary Surgery for Biopsy-Diagnosed Pure Ductal Carcinoma In Situ (DCIS) of the Breast. Modern Pathology. 2026. doi:10.1016/j.modpat.2026.101040

BibTeX
@article{Riggi2026,
  author = {Riggi, Julia A M and Galant, Christine and Bouzin, Caroline and Daumerie, Aurélie and Benhaddi, Naïma and Vernaeve, Hilde and Dubois, Nathanael and Vassilieff, Maud and Roman, Mirela and Fellah, Latifa and Gerday, Amandine and van Deurzen, Carolien H M and Berlière, Martine and Van Bockstal, Mieke R},
  title = {An Immunohistochemistry-based Decision Flowchart to De-escalate Axillary Surgery for Biopsy-Diagnosed Pure Ductal Carcinoma In Situ (DCIS) of the Breast},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2026.101040}
}
Kostenlos starten →